HK1129205A1 - Adjuvant-sparing multi-dose influenza vaccination regimen - Google Patents

Adjuvant-sparing multi-dose influenza vaccination regimen

Info

Publication number
HK1129205A1
HK1129205A1 HK09108245.7A HK09108245A HK1129205A1 HK 1129205 A1 HK1129205 A1 HK 1129205A1 HK 09108245 A HK09108245 A HK 09108245A HK 1129205 A1 HK1129205 A1 HK 1129205A1
Authority
HK
Hong Kong
Prior art keywords
sparing
adjuvant
vaccination regimen
influenza vaccination
dose influenza
Prior art date
Application number
HK09108245.7A
Other languages
English (en)
Inventor
Giudice Giuseppe Del
Riccardo Manetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1129205(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1129205A1 publication Critical patent/HK1129205A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK09108245.7A 2006-06-15 2009-09-08 Adjuvant-sparing multi-dose influenza vaccination regimen HK1129205A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81466506P 2006-06-15 2006-06-15
PCT/IB2007/002724 WO2007144772A2 (fr) 2006-06-15 2007-06-15 Régime de vaccination multidose à adjuvant limité contre la grippe

Publications (1)

Publication Number Publication Date
HK1129205A1 true HK1129205A1 (en) 2009-11-20

Family

ID=38832174

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09108245.7A HK1129205A1 (en) 2006-06-15 2009-09-08 Adjuvant-sparing multi-dose influenza vaccination regimen

Country Status (18)

Country Link
US (3) US20090220545A1 (fr)
EP (1) EP2032163B1 (fr)
JP (2) JP5566687B2 (fr)
KR (1) KR20090016704A (fr)
CN (1) CN101500603A (fr)
AU (1) AU2007258874B2 (fr)
BR (1) BRPI0713150A8 (fr)
CA (1) CA2657989A1 (fr)
CY (1) CY1114315T1 (fr)
DK (1) DK2032163T3 (fr)
EA (1) EA017441B1 (fr)
ES (1) ES2401484T3 (fr)
HK (1) HK1129205A1 (fr)
PL (1) PL2032163T3 (fr)
PT (1) PT2032163E (fr)
SI (1) SI2032163T1 (fr)
WO (1) WO2007144772A2 (fr)
ZA (1) ZA200810582B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DK2368572T3 (da) * 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
EP2889042A3 (fr) * 2008-03-18 2015-10-14 Novartis AG Améliorations dans la préparation d'antigènes de vaccin contre le virus de la grippe
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
KR101176305B1 (ko) * 2009-10-14 2012-08-23 웅진코웨이주식회사 붉나무 추출물을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
US20110126501A1 (en) 2009-10-16 2011-06-02 Woongjin Coway Co., Ltd. Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter
KR101153630B1 (ko) * 2009-10-16 2012-06-18 웅진코웨이주식회사 타닌산을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
WO2011102873A1 (fr) * 2010-02-21 2011-08-25 Innovative Bottles, Llc Contenant pharmaceutique biodégradable et capuchon de sécurité
WO2012082165A1 (fr) * 2010-01-24 2012-06-21 Novartis Ag Microparticules de polymère biodégradable irradiées
US8852157B2 (en) 2010-02-21 2014-10-07 Innovative Bottles, Llc Disposable items made from bioplastic resins
DK2569007T3 (en) * 2010-05-11 2016-01-25 Intervet Int Bv VACCINE AGAINST Mycoplasma hyopneumoniae SUITABLE FOR ADMINISTRATION IN PRESENCE OF maternally derived antibodies
JP6191082B2 (ja) * 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン
EP3791891A1 (fr) 2014-07-17 2021-03-17 Brian J. Czerniecki Identification de peptides immunogènes du cmh de classe ii pour l'immunothérapie
WO2017014810A1 (fr) * 2015-07-17 2017-01-26 Czerniecki Brian J Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
KR102455905B1 (ko) * 2014-10-30 2022-10-17 추가이 세이야쿠 가부시키가이샤 시린지 캡을 구비한, 침 부착 프리필드 시린지 제제
SG11201706247VA (en) 2015-02-03 2017-08-30 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
JP2021533157A (ja) * 2018-08-07 2021-12-02 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
WO2021041624A2 (fr) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Virus de la grippe recombinants à ha stabilisé pour réplication dans des oeufs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241926A (en) * 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
WO1990001948A1 (fr) 1988-08-25 1990-03-08 The Liposome Company, Inc. Vaccin contre la grippe et nouveaux adjuvants
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
MXPA05013973A (es) * 2003-06-17 2006-03-02 Mannkind Corp Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
CA2559371C (fr) * 2004-03-09 2014-07-08 Chiron Corporation Vaccins antigrippaux
NZ561823A (en) 2005-03-23 2010-04-30 Glaxosmithkline Biolog Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
EP1945253A2 (fr) * 2005-11-04 2008-07-23 Novartis Vaccines and Diagnostics S.r.l. Voies d'administration pour sensibilisation/stimulation par des vaccins contre la grippe
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2043682B1 (fr) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Vaccin anti-grippal

Also Published As

Publication number Publication date
BRPI0713150A8 (pt) 2017-08-22
US20120039934A1 (en) 2012-02-16
ES2401484T3 (es) 2013-04-22
JP2014098038A (ja) 2014-05-29
WO2007144772A2 (fr) 2007-12-21
EA017441B1 (ru) 2012-12-28
US8808686B2 (en) 2014-08-19
EP2032163B1 (fr) 2013-01-23
AU2007258874A1 (en) 2007-12-21
ZA200810582B (en) 2009-09-30
CY1114315T1 (el) 2016-08-31
CN101500603A (zh) 2009-08-05
JP5981951B2 (ja) 2016-08-31
PL2032163T3 (pl) 2013-06-28
PT2032163E (pt) 2013-04-11
CA2657989A1 (fr) 2007-12-21
AU2007258874B2 (en) 2013-11-14
KR20090016704A (ko) 2009-02-17
US20090220545A1 (en) 2009-09-03
DK2032163T3 (da) 2013-03-25
BRPI0713150A2 (pt) 2012-03-27
SI2032163T1 (sl) 2013-05-31
EP2032163A2 (fr) 2009-03-11
JP5566687B2 (ja) 2014-08-06
EA200970013A1 (ru) 2009-06-30
US20140370053A1 (en) 2014-12-18
WO2007144772A3 (fr) 2008-03-27
JP2009539965A (ja) 2009-11-19
US9901630B2 (en) 2018-02-27

Similar Documents

Publication Publication Date Title
ZA200810582B (en) Adjuvant-sparing multi-dose influenza vaccination regimen
IL196024A0 (en) Influenza vaccine
HK1143085A1 (en) Low-additive influenza vaccines
PT2043682E (pt) Vacina da influenza
GB0607088D0 (en) Vaccine
GB0810305D0 (en) Influenza vaccination
EP1998814A4 (fr) Nouveaux vaccins contre l'influenza m2
ZA200809056B (en) Influenza virus vaccine
HK1129836A1 (zh) 疫苗
EP2318044A4 (fr) Vaccins contre la grippe
ZA200901592B (en) Vaccine
EP2240199A4 (fr) Vaccins contre la grippe b
ZA200900062B (en) Influenza vaccine
GB0625593D0 (en) Vaccine
GB0623865D0 (en) Influenza vaccine
GB0618195D0 (en) Influenza vaccine
GB0619090D0 (en) Influenza vaccine
GB0623218D0 (en) Influenza vaccine
GB0625453D0 (en) Influenza vaccine
GB0723987D0 (en) Influenza vaccine reagents
GB0620336D0 (en) Vaccine
GB0619824D0 (en) Vaccine
GB0619820D0 (en) Vaccine
GB0614254D0 (en) Vaccine
GB0620815D0 (en) Vaccine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230615